CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation
READ MORECAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) ("Evelo" or the "Company"), a clinical stage biotechnology company
READ MORECAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of
READ MOREQuarterly Filings. 0001694665-23-000182.pdf. 0001694665-23-000182.rtf. 0001694665-23-000182.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. The Investor Relations website contains information about Evelo Biosciences''s business for stockholders, potential investors, and financial analysts.
READ MORECAMBRIDGE, Mass. and LONDON, June 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies, announced today
READ MOREEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial
READ MORESEC Filing Announcement - Evelo. View Evelo''s SEC filings. Direct all inquiries to evelo@vlpc . © Evelo Biosciences, Inc.
READ MORECAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a new modality of
READ MOREEvelo Biosciences Phase 2 Clinical Study with EDP2939 Does Not Achieve Primary Endpoint (Updated - October 17, 2023 7:03 AM EDT) Evelo Biosciences, Inc. (Nasdaq: NASDAQ:EVLO) today announced top
READ MOREAbout us. Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic
READ MOREEvelo Biosciences Inc. Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio
READ MOREEvelo Leadership Team Home / Who We Are / Leadership Team Leadership Team Simba Gill, Ph.D. Chief Executive Officer View Biography Mark Bodmer, Ph.D. President of R&D, Chief Scientific Officer View Biography Andrea Itano, Ph.D.
READ MORECAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company
READ MOREEvelo Biosciences, Inc. Common Stock (EVLO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
READ MORECAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) ("Evelo" or the "Company"), a clinical stage biotechnology company developing a novel platform of
READ MORECAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation
READ MOREEvelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that are designed to act on the small intestinal axis, SINTAX, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems.
READ MORE-- EDP1908 demonstrates potent anti-tumor effects in murine models of cancer -- -- Oral extracellular vesicles have potential to be a completely novel mechanism of I/O therapy -- CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a
READ MORECAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation
READ MOREEvelo Biosciences, Inc. (),,,21, 1261,:,:,:EDP-1815,EDP-1867,EDP-1066,EDP-2939,EDP-1908。
READ MORE2 · Evelo Biosciences Inc 주가가 실시간인 경우 이 페이지에는 OTC EVLO 증권 거래소 데이터가 표시됩니다. 개장 전 EVLO 주가를 확인하거나 시간 외 시세를 확인할 수 있습니다. 아래 Evelo Biosciences Inc 실시간 주가 차트에서 최신 움직임을 모니터링하세요.
READ MORECAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis (SINTAX) today announced updates to its clinical pipeline as well as business updates.
READ MORECAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company
READ MORECAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced updates to its clinical programs. "In the fourth cohort of the
READ MOREEvelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™,
READ MOREDJ. TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform. 23-10-18. MT. Morgan Stanley Adjusts Evelo Biosciences'' Price Target to $10 From $2, Keeps Equalweight Rating. 23-07-26. MT. Chardan Downgrades Evelo Biosciences to Neutral From Buy, Cuts Price Target to $2.50 From $5. 22-11-16.
READ MOREEvelo Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share amounts) June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 7,622 $ 47,940 Prepaid expenses and
READ MOREEvelo Biosciences。. 4、 Evelo Biosciences. 2022525, Evelo Biosciences（：EVLO） 1.46 54,246,358
READ MORECAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of
READ MORE